Cancer News and Research

Latest Cancer News and Research

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Prostate cancer tests promised but not delivered

Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.

16 Dec 2009

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

Italian patent issued for NPM1 to test patients with AML

Xenomics, Inc., a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issued.

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

UCLA researchers find link between brain cancer and fatty acid synthesis

Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

16 Dec 2009

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry.

16 Dec 2009

Stress and alcohol can trigger domestic violence during holiday season

The holidays are supposed to be a time for family togetherness and cheer, yet for many women and children, they are instead a time of fear and violence.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Cancer News and Research

Latest Cancer News and Research

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Prostate cancer tests promised but not delivered

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Discovery may yield new treatments for hormone-resistant prostate cancer

Italian patent issued for NPM1 to test patients with AML

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

UCLA researchers find link between brain cancer and fatty acid synthesis

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Stress and alcohol can trigger domestic violence during holiday season

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Novartis submits JOULFERON MAA to the EMEA

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in